Please assess the completion status of the following clinical trial:

Trial Title: A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ongoing participants from any completed global Roche-sponsored Herceptin trial~* Participants enrolled in any Roche-sponsored Herceptin trial who have at least stable disease (or whose disease has not recurred) during Herceptin therapy at the end of the lead-in trial~* Available study termination data (including tumor assessment and laboratory data) on the Case Report Form for the lead-in trial~* Judged eligible by the investigator following a thorough risk/benefit assessment, if signs of chronic heart failure developed during the lead-in trial~Exclusion Criteria:~* Pregnant or nursing women~* Women of childbearing potential unless using effective contraception as determined by the investigator~* Severe dyspnea at rest requiring supplementary oxygen therapy~* Severe uncontrolled systemic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Herceptin (Type: EXPERIMENTAL): Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).